Company news: Bausch + Lomb and ISTA; Sanofi and Regeneron

Share this article:
Eye care giant Bausch + Lomb is buying ISTA Pharmaceuticals for $500 million. ISTA brings to Bausch + Lomb a portfolio of eye health drugs including non-steroidal, anti-inflammatory, allergy, glaucoma and spreading agents. ISTA's pipeline, featuring therapies to treat inflammation and pain, complements Bausch + Lomb's, which includes the first of a new class of ocular anti-inflammatory agents to come along in decades, said the companies. The transaction is subject to regulatory approval and the assent of ISTA's shareholders.

Sanofi and Regeneron's experimental cholesterol drug lowers LDL cholesterol by up to 72% in a Phase 2 trial involving 183 patients, the companies reported at the American College of Cardiology meeting in Chicago. The drug is one of a new class called PCSK9 inhibitors, including compounds in development by Amgen, Pfizer and Merck.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.